P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3
Main Authors: | B. D. Shah, R. D. Cassaday, J. H. Park, R. Houot, O. O. Oluwole, A. C. Logan, N. Boissel, T. Leguay, M. R. Bishop, M. S. Topp, D. Tzachanis, K. M. O’Dwyer, M. L. Arellano, Y. Lin, M. R. Baer, G. J. Schiller, M. Subklewe, M. Abedi, M. C. Minnema, W. G. Wierda, D. J. DeAngelo, P. Stiff, D. Jeyakumar, J. Dong, S. Adhikary, L. Zhou, P. C. Schuberth, B. Kharabi Masouleh, A. Ghobadi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844312.20412.89 |
Similar Items
-
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
by: Bijal D. Shah, et al.
Published: (2022-12-01) -
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
by: Daniel J DeAngelo, et al.
Published: (2023-08-01) -
P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2
by: M. L. Wang, et al.
Published: (2022-06-01) -
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
by: Alan S. Wayne, et al.
Published: (2022-10-01) -
P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT
by: Bijal Shah, et al.
Published: (2023-08-01)